Schizophrenia Clinical Trials in Decatur, Georgia

11 studies are recruiting for schizophrenia in Decatur, Georgia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia

   The purpose of this clinical trial is to learn whether the investigational drug LTX-001 is safe and well tolerated in adults with a diagnosis of schizophrenia who are having a recent worsening of their symptoms (an acute exacerbation). Additional questions it aims to answer are: * how does the amou…

   Stage

   Phase 1

   Ages

   18 to 55

   Site

   CenExel iResearch, LLC, Decatur, Georgia

   Locations

   10 in total

   Run by

   Leal Therapeutics, Inc

   See if you can join NCT07734493 on ClinicalTrials.gov

2. A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT

   A study to evaluate the safety, tolerability, and PK of an injectable form of KarXT in participants with schizophrenia

   Stage

   Phase 1

   Ages

   18 to 55

   Site

   CenExel iResearch, LLC, Decatur, Georgia

   Locations

   8 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07061288 on ClinicalTrials.gov

3. A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

   ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Clinical Site, Decatur, Georgia

   Locations

   42 in total

   Run by

   MapLight Therapeutics

   See if you can join NCT07459647 on ClinicalTrials.gov

4. Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

   To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine

   Stage

   Phase 3

   Ages

   10 to 17

   Site

   Alkermes Investigator Site, Decatur, Georgia

   Locations

   47 in total

   Run by

   Alkermes, Inc.

   See if you can join NCT05303064 on ClinicalTrials.gov

5. Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder

   This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.

   Stage

   Phase 1

   Ages

   10 to 17

   Site

   Bioxcel Clinical Research Site, Decatur, Georgia

   Locations

   5 in total

   Run by

   BioXcel Therapeutics Inc

   See if you can join NCT05025605 on ClinicalTrials.gov

6. A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

   Evaluate the efficacy and safety of Ulotaront (SEP-363856) in acutely psychotic subjects with schizophrenia

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   CenExel IRA (CenExcel iResearch, LLC) Site, Decatur, Georgia

   Locations

   73 in total

   Run by

   Otsuka Pharmaceutical Development & Commercialization, Inc.

   See if you can join NCT06894212 on ClinicalTrials.gov

7. Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

   The purpose of this study is to assess the efficacy, safety, and tolerability of GXV813 in the treatment of an acute episode of schizophrenia

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   CenExel iResearch, Decatur, Georgia

   Locations

   16 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT07467993 on ClinicalTrials.gov

8. NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

   This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Neurocrine Clinical Site, Decatur, Georgia

   Locations

   57 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT07114874 on ClinicalTrials.gov

9. NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

   The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Neurocrine Clinical Site, Decatur, Georgia

   Locations

   21 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT06963034 on ClinicalTrials.gov

10. Safety and Tolerability of Open-Labeled Iloperidone in Adolescents

    To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.

    Stage

    Phase 4

    Ages

    12 to 17

    Site

    Vanda Investigational Site, Decatur, Georgia

    Locations

    9 in total

    Run by

    Vanda Pharmaceuticals

    See if you can join NCT05648591 on ClinicalTrials.gov

11. Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

    This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg or 50 mg once daily over 4 weeks, then in the long-term flexible doses 15-50mg daily over a period o…

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Reviva site, Decatur, Georgia

    Locations

    18 in total

    Run by

    Reviva Pharmaceuticals

    See if you can join NCT05184335 on ClinicalTrials.gov